Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
IPO Year: 2019
Exchange: NASDAQ
Website: oysterpointrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2022 | $22.00 | Buy | Chardan Capital Markets |
| 7/18/2022 | $20.00 | Buy | H.C. Wainwright |
| 11/9/2021 | $30.00 → $23.00 | Overweight → Neutral | JP Morgan |
Submission status for OYSTER POINT PHARMA INC's drug TYRVAYA (ORIG-1) with active ingredient VARENICLINE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 213978, Application Classification: Type 3 - New Dosage Form
15-12G - Oyster Point Pharma, Inc. (0001720725) (Filer)
8-K/A - Oyster Point Pharma, Inc. (0001720725) (Filer)
EFFECT - Oyster Point Pharma, Inc. (0001720725) (Filer)
25-NSE - Oyster Point Pharma, Inc. (0001720725) (Subject)
S-8 POS - Oyster Point Pharma, Inc. (0001720725) (Filer)
S-8 POS - Oyster Point Pharma, Inc. (0001720725) (Filer)
S-8 POS - Oyster Point Pharma, Inc. (0001720725) (Filer)
S-8 POS - Oyster Point Pharma, Inc. (0001720725) (Filer)
POS AM - Oyster Point Pharma, Inc. (0001720725) (Filer)
8-K - Oyster Point Pharma, Inc. (0001720725) (Filer)
Chardan Capital Markets initiated coverage of Oyster Point Pharma with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Oyster Point Pharma with a rating of Buy and set a new price target of $20.00
JP Morgan downgraded Oyster Point Pharma from Overweight to Neutral and set a new price target of $23.00 from $30.00 previously
PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that William J. Link, Ph.D., is retiring from Oyster Point's Board of Directors, effective as of March 17, 2022. Dr. Link will continue to serve as a consultant to the company. "On behalf of the entire Oyster Point organization, we are eternally thankful to Dr. Link for his leadership and significant contributions over the years," said Jeffrey Nau, M.M.S, Ph.D., president and chief executive officer, Oy
PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the appointment of a new Director and Chairperson to its Board of Directors. The Oyster Point Pharma Board of Directors is pleased to announce the appointment of Donald Santel as non-executive Chairperson and a Director of the Company and a member of the Compensation Committee. Don joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, M.D. steps down as Chairperson, remaining a
PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the appointment of Marian Macsai, M.D., as Chief Medical Officer, and Eric Carlson, Ph.D., as Chief Scientific Officer, both of whom will join the executive leadership team, effective December 7, 2020. “I’m thrilled to welcome Drs. Macsai and Carlson to the executive leadership team at Oyster Point, as both will help expand and strengthen our organization during this time of unprecedented growth,” said
PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to three new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. Each stock option has an exercise price equal to $11.20 per share, Oyster Point Pharma's
NEW YORK, NY / ACCESSWIRE / November 12, 2022 / Ritchie Bros. Auctioneers Incorporated (NYSE:RBA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of IAA, Inc. to RBA for $10.00 per share in cash and 0.5804 shares of RBA common stock for each share of IAA common stock.If you are an RBA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Point Pharma, Inc. (NASDAQ:OYST)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connecti
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covered to DateOyster Point Pharma to be Acquired by Viatris, with the Transaction Expected to Close During Q1'23Enrollment Completed in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopat
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma"), today announced that it has entered into a definitive agreement under which Viatris Inc. (NASDAQ:VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmolo
PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time. Conference Call DetailsTo access the live call by phone, please register here to receive dial-in details or to select a call back. Webcast DetailsThe webcast will be made available on the compa
PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 14,400 shares of common stock to seven new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. Each stock option has an exercise price equal to $8.08 per share, Oyster Point Pharma's closing
PRINCETON, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to three new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. Each stock option has an exercise price equal to $5.87 per share, Oyster Point Pharma's closing
PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago, Illinois from September 28-29, 2022. "We look forward to presenting our post-hoc analyses on the clinical benefits of TYRVAYA® (varenicline solution) Nasal Spray as well as the results of evaluating inflammatory cytokine levels in tears in healthy and dry eye
PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 242,600 shares of common stock to 36 new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. 242,600 stock options were granted and have exercise prices ranging from $6.25 to $12.44 per sha
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022. "We look forward to this year's WIO Summer Symposium, a curated meeting for women offering content in all subjects of importance to women ophthalmologists," said Marian Macsai, MD chief medical officer, Oyster Point Pharma. "Collectively, the TYRVAYA
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covered to DateOyster Point Pharma to be Acquired by Viatris, with the Transaction Expected to Close During Q1'23Enrollment Completed in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopat
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma"), today announced that it has entered into a definitive agreement under which Viatris Inc. (NASDAQ:VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmolo
PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time. Conference Call DetailsTo access the live call by phone, please register here to receive dial-in details or to select a call back. Webcast DetailsThe webcast will be made available on the compa
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2'22Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 5,700 Unique Eye Care Professionals; Launch to Date, Approximately 7,700 Unique Eye Care Professionals Have Written Prescriptions for TYRVAYAExpanded Patient Access to TYRVAYA, With Medicare Part D Access Expected by Q4'22, and As Early As September 2022Operating Expense Streamlining Plan to Maximize Commercial Potential of TYRVAYA and Create Value for ShareholdersContinuing Enrollment of Subjects in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopathy, with Study Results Ex
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time. Conference Call DetailsTo access the live call by phone, please register here to receive dial-in details or to select a ca
TYRVAYA® Nasal Spray Net Product Revenue of $2.7 Million in Q1'22Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care ProfessionalsExpansion of Commercial Coverage for TYRVAYA, with Up to Approximately 95 Million Lives Covered to DateLicensing Partner, Ji Xing Pharmaceuticals, Authorized to Conduct Phase 3 Clinical Trial of OC-01 in ChinaContinuing Enrollment of Subjects in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopathy, with Study Results Expected in 2H 2022Additional Pre-Clinical Studies Underway for Enriched Tear Film Gene Therapy to Target Stages 2 and 3 Neurotrophic KeratopathyConference C
PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time. Conference Call DetailsTo access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International). The conference ID number is 4149318. A telephone replay will be avai
FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in Q4'21, plus $5.4 Million Recognized from Ji Xing Pharmaceuticals (Ji Xing) License Agreement in Q4'21Over 5,500 TYRVAYA Prescriptions Filled; Prescriptions Written by Approximately 1,900 Unique Eye Care Professionals in November and December 2021$50 Million Drawn on Second Tranche from OrbiMed Royalty & Credit Opportunities III, LP (OrbiMed), Cash Received on November 4, 2021Continue to Enroll OLYMPIA Phase 2 Clinical Trial, Study Results Expected in 2H 2022Conference Call and Webcast Scheduled fo
PRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time. Conference Call Details To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International). The conference ID number is 7788145. A teleph
FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021Field Force Onboarding Completed During Q3'21, U.S. Launch of TYRVAYA Nasal Spray Initiated on Nov. 1st. TYRVAYA is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies$17.9 Million in Revenue Recognized from Ji Xing Pharmaceuticals (Ji Xing) During Q3'21Following FDA Approval of TYRVAYA Nasal Spray on October 15th, Company Received $5 Million Development Milestone Payment and the Remaining Senior Common Shares in Ji XingWaiver and Amendment to the OrbiMed Credit Agreement and Exercise of Option to Borrow the Second $50 Million Tra
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
4 - Oyster Point Pharma, Inc. (0001720725) (Issuer)
SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13G - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13G/A - Oyster Point Pharma, Inc. (0001720725) (Subject)
SC 13D/A - Oyster Point Pharma, Inc. (0001720725) (Subject)